Breaks Categories: Stock Spotlights

FridayApr 16, 2021 2:42 pm

BioMedNewsBreaks – RYAH Group Inc.’s Products Facilitate Personalized Therapies, Remote Patient Monitoring

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, has created a range of smart devices set to disrupt the future of medicine. RYAH Group, which is on a mission to advance the world’s transition to remote-health solutions, has done precisely that with its remote health platform called RYAH MD. “RYAH MD is a service that allows clinicians to remotely monitor and control patients’ dosing regimens with RYAH’s dose-measuring products. It provides necessary information that doctors can analyze to learn how different dosing variables affect outcomes. RYAH MD allows the doctor to recommend parameters on…

Continue Reading

FridayApr 16, 2021 1:48 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market

Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of 13.6%. These figures are according MarketsandMarkets, which cites several growth factors including technological advancements in fluid management systems (https://ibn.fm/rKWZC). As disposal of waste fluids presents a unique set of challenges for every health care facility, Skyline Medical offers a clear solution. Skyline’s patented and FDA-cleared STREAMWAY System is “the new standard in waste fluid management,” automating the collection, measurement and…

Continue Reading

FridayApr 16, 2021 1:24 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the…

Continue Reading

FridayApr 16, 2021 1:08 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Eyes Q2 Expansion of Growing Portfolio

Healthy Extracts (OTCQB: HYEX) recently released its full-year 2020 report. In addition to achieving a 71% jump in its revenue on the back of a plant-based industry boom, the company announced it was at an advanced stage of clinical testing that would culminate in the release of a new product in Q2 2021. The proprietary Fuel4Thought Brain Booster product will add to Health Extracts’ portfolio, which has increased thanks to acquisitions. An article on the developments reads, “Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary formulations derived from the rare Citrus…

Continue Reading

ThursdayApr 15, 2021 2:18 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. at Forefront to Speed Economic Recovery

United Medical Equipment (“UME,” “UMEBSNI”) is well-positioned to help speed up economic recovery with its FDA-approved COVID-19 rapid test kits. This comes as governments in different parts of the world have expressed interest in rapid testing, citing health and economic benefits. An article on the matter reads, “New York City is wasting no time to leverage the power of this low-cost, high impact option as the city has announced the launch of its Forward Rapid-Test Program. The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The…

Continue Reading

ThursdayApr 15, 2021 11:39 am

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs.…

Continue Reading

ThursdayApr 15, 2021 11:22 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Delivering Readily-Available Solution Amid Growing Need

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, is fulfilling a growing need for improved neurological monitoring that is cost efficient, disposable and portable. When combating a highly contagious disease, disposable technology helps to ensure that the virus is not spread through equipment. Brain Scientific’s disposable EEG caps are designed for single use and also assist in shortening person-to-person contact due to ease of placement, decreasing transmission between staff and patient. “As health-care facilities and frontline workers move quickly to address COVID symptoms and provide effective treatment, disposable devices offer a solution to rapidly…

Continue Reading

ThursdayApr 15, 2021 11:11 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Targets $400M Slice of Massive Global Endoscopy Market

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has hailed its first product, the i/Blue(TM) Imaging System, as a breakthrough technology that will advance the accuracy and efficiency of bladder cancer detection and removal, thus helping it capture some market share. The global endoscopy market is valued at $46 billion, of which Imagin is positioned to target $400 million with its bladder cancer detection product. An article detailing this reads, “The company’s patented ultrasensitive imaging product based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.” According to…

Continue Reading

FridayApr 09, 2021 12:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models

Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical…

Continue Reading

ThursdayApr 08, 2021 2:20 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants has remained alive and cancer-free as of the most recent evaluation late last year, while two other patients in the small study saw reductions of greater than 25% (one being an 80% reduction) in the…

Continue Reading